Close Menu

NEW YORK – Researchers are beginning to uncover biomarkers to help guide treatment for small cell lung cancer, which to date has not benefited from precision oncology advances.

Small cell lung cancer is an aggressive disease that accounts for about 15 percent of all lung cancers. While patients often initially respond to chemotherapy, the disease typically becomes resistant quickly, and the search for biomarkers that might predict treatment response has been hampered by tissue availability.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.